Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer

International Journal of Colorectal Disease

Volumn 24, Issue 6, 2009, Pages 629-639

  Zhang, Yan Jie ^a,b   Zhao, Shu Liang ^a   Tian, Xiao Qing ^a,c   Sun, Dan Feng ^a   Xiong, Hua ^a   Dai, Qiang ^b   Li, Xiao Qiang ^b   Fang, Jing Yuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b University School of Medicine   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Colorectal cancer; Methylation; mTOR; Rapamycin; Signal transduction

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MONOTHERAPY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; AZACITIDINE; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DRUG SYNERGISM; HCT116 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; TUMOR BURDEN;

EID: 67349119907     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-009-0664-8     Document Type: Article

References (48)

1. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124(3):471-484
2. Easton JB, Houghton PJ (2006) mTOR and cancer therapy. Oncogene 25(48):6436-6446
3. Seeliger H, Guba M, Kleespies A et al (2007) Role of mTOR in solid tumor systems: A therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 26(3-4):611-621
4. Abraham RT, Eng CH (2008) Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin Ther Targets 12(2):209-222
5. Guba M, Koehl GE, Neppl E et al (2005) Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 18(1):89-94
6. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449-456
7. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281
8. Cloughesy TF, Yoshimoto K, Nghiemphu P et al (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5(1):e8
9. Rizzieri DA, Feldman E, Dipersio JF et al (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14(9):2756-2762
10. Ansell SM, Inwards DJ, Rowland KM Jr et al (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment Group. Cancer 113(3):508-514
11. Fujishita T, Aoki K, Lane HA (2008) Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci USA 105(36):13544-13549
12. Jimeno A, Rudek MA, Kulesza P et al (2008) Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol 26(25):4172-4179
13. Elit L (2002) CCI-779 Wyeth. Curr Opin Investig Drugs 3(8):1249-1253
14. Nozawa H, Watanabe T, Nagawa H (2007) Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett 251(1):105-113
15. Sun Q, Liu Q, Zheng Y et al (2008) Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. Mol Immunol 45(10):2929-2936
16. Buck E, Eyzaguirre A, Brown E et al (2006) Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5(11):2676-2684
17. Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525-537
18. O'Reilly KE, Rojo F, She QB et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508
19. Zhang YJ, Fang JY, Sun DF et al (2007) Synergistic effect of rapamycin (RPM) and PD98059 on cell cycle and mTOR signal transduction in human colorectal cancer cells. Zhonghua Zhong Liu Za Zhi 29(12):889-893 (In Chinese, with English abstract)
20. Lu R, Wang X, Chen ZF et al (2007) Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decrease DNA methylation in colon cancer cells. J Biol Chem 282(16):12249-12259
21. Rodriguez J, Frigola J, Vendrell E et al (2006) Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res 66(17):8462-8468
22. Wilson AS, Power BE, Molloy PL (2007) DNA hypomethylation and human diseases. Biochim Biophys Acta 1775(1):138-162
23. Fang JY, Lu R, Mikovits JA et al (2006) Regulation of hMSH2 and hMLH1 expression in the human colon cancer cell line SW1116 by DNA methyltransferase 1. Cancer Lett 233(1):124-130
24. Fang JY, Lu J, Chen YX, Yang L (2003) Effects of DNA methylation on expression of tumor suppressor genes and proto-oncogene in human colon cancer cell lines. World J Gastroenterol 9(9):1976-1980
25. Kantarjian H, Issa JP, Rosenfeld CS et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803
26. Appleton K, Mackay HJ, Judson I et al (2007) Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25(29):4603-4609
27. Momparler RL (2005) Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Semin Oncol 32:443-451
28. Ghoshal K, Bai S (2007) DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc) 43(6):395-422
29. Lu R, Wang X, Fang JY (2007) The demethylating agent 5-aza-2-deoxycytidine prevents tumorigenesis in a mouse model of colorectal cancer. Chinese Journal of Digestion 27(5):307-310 (In Chinese, with English abstract)
30. Plumb JA, Strathdee G, Sludden J et al (2000) Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60:6039-6044
31. Kanda T, Tada M, Imazeki F et al (2005) 5-Aza-2′-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. Oncol Rep 14:975-979
32. Petak I, Danam RP, Tillman DM et al (2003) Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ 10:211-217
33. Sharma D, Saxena NK, Davidson NE et al (2006) Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res 66:6370-6378
34. Faivre S, Djelloul S, Raymond E (2006) New paradigms in anticancer therapy: Targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 33(4):407-420
35. Wils J (2007) Adjuvant treatment of colon cancer: Past, present and future. J Chemother 19(2):115-122
36. Wang X, Sun DF, Fang JY (2006) Research advances on the relationship of PI3-kinase/Akt/mTOR pathway and epigenetic modification. Yi Chuan 28(12):1585-1590 (In Chinese, with English abstract)
37. Goel A, Arnold CN, Niedzwiecki D et al (2004) Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 64(9):3014-3021
38. Sun D, Toan X, Zhang Y et al (2008) Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines. Sci China C Life Sci 51(7):640-647
39. Zhang YJ, Dai Q, Wu SM et al (2008) Susceptibility for NSAIDs-induced apoptosis correlates to p53 gene status in gastric cancer cells. Cancer Invest 26(9):868-877
40. McCabe MT, Low JA, Daignault S et al (2006) Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 66:385-392
41. Zorn CS, Wojno KJ, McCabe MT et al (2007) 5-Aza-2′-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin Cancer Res 13(7):2136-2143
42. Nathan CO, Amirghahari N, Rong X et al (2007) Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 67(5):2160-2168
43. Hamilton SR, Vogelstein B, Kudo S et al (2001) Tumours of the colon and rectum. In: Hamilton SR, Aaltonen L (eds) Pathology and genetics of tumours of the digestive system. World Health Organization classification of tumours. IARC Press, Lyon, pp 104-119
44. Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly IV infusion of CCI-779, a novel mTOR inhibitor, in patient with cancer. J Clin Oncol 22:2336-2347
45. Granville CA, Warfel N, Tsurutani J et al (2007) Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 13(7):2281-2289
46. Wyeth Pharmaceuticals, Inc. (2005) Rapamune (sirolimus) oral solution/ tablets, package insert.
47. Vazquez F, Devreotes P (2006) Regulation of PTEN function as a PIP3 gatekeeper through membrane interaction. Cell Cycle 51(14):523-527
48. Goel A, Nagasaka T, Arnold CN et al (2007) The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132(1):127-138